New Clinical Trial Reveals Solriamfetol Significantly Improves Alertness and Performance in Early Morning Shift Workers Battling Severe Fatigue
The modern economy operates on a 24-hour cycle, sustained by millions of individuals who wake long before the sun rises to keep critical infrastructure, healthcare facilities, transportation networks, and supply chains moving. While overnight schedules frequently dominate discussions surrounding fatigue and circadian disruption, a far greater proportion of the workforce is employed on early morning shifts. Despite the ubiquity of these schedules, a glaring blind spot has long existed in clinical research regarding how to safely and effectively manage the severe sleepiness experienced by those who start their days in the dead of night.
A landmark clinical trial recently led by researchers at Mass General Brigham has taken a significant step toward addressing this oversight. Published in the esteemed journal NEJM Evidence, the study evaluated the wake-promoting medication solriamfetol, marketed under the brand name Sunosi, in early morning shift workers diagnosed with shift work disorder (SWD). The results demonstrated that the therapy successfully mitigated excessive daytime sleepiness, enhanced cognitive function, and prolonged wakefulness during simulated work hours without gravely compromising subsequent recovery sleep. This breakthrough sheds light on a pervasive occupational health challenge that affects millions yet has historically received minimal pharmacological attention.
Understanding the Scale and Mechanics of Circadian Disruption
To fully grasp the implications of the Mass General Brigham study, one must examine the broader socioeconomic and physiological landscape of modern work arrangements. Epidemiological data indicates that roughly one in four workers in industrialized nations operates outside the traditional Monday-through-Friday, 9-to-5 paradigm. Within this substantial demographic, early-morning risers—those whose shifts typically commence between 3:00 a.m. and 7:00 a.m.—represent the largest single segment of non-traditional shift workers.
Paradoxically, many individuals caught in this cycle do not self-identify as shift workers. Instead, they view their routine merely as an early start to a standard day, failing to recognize that their biology is waging a constant war against their schedule. The human body is governed by an internal master clock located in the suprachiasmatic nucleus of the hypothalamus, which regulates circadian rhythms, hormone secretion, body temperature fluctuations, and sleep-wake cycles. This biological clock is tightly synchronized with the earth’s natural light-dark cycle, programming the brain to experience peak sleepiness during the pre-dawn hours, specifically between midnight and 7:00 a.m.
When an employee awakens at 3:00 a.m. to begin a shift, they are forcing consciousness upon a brain that is biologically hardwired for deep sleep. This creates what sleep specialists describe as a double burden. During work hours, these individuals must contend with overwhelming biological pressure to sleep, which severely degrades concentration, reaction time, and decision-making capabilities. Conversely, when their shift concludes in the early afternoon, they attempt to sleep during a period when circadian alerting signals are rising, making it profoundly difficult to achieve restorative, uninterrupted rest. Over time, this chronic misalignment culminates in shift work disorder, a recognized medical condition characterized by persistent insomnia, excessive daytime sleepiness, and functional impairment.
The Hidden Toll: Health, Safety, and Economic Consequences
The ramifications of shift work disorder extend far beyond mere tiredness, casting a long shadow over public health, occupational safety, and economic productivity. Chronic sleep deprivation and circadian misalignment are independent risk factors for a host of long-term medical conditions, including cardiovascular disease, metabolic syndrome, type 2 diabetes, gastrointestinal disorders, and certain forms of cancer, as recognized by the International Agency for Research on Cancer.
In the immediate term, however, the hazards manifest most acutely in terms of human error. Cognitive faculties such as sustained attention, working memory, executive function, and psychomotor vigilance deteriorate rapidly under the weight of severe sleep debt. Consequently, early morning shift workers face an elevated risk of occupational injuries, machinery accidents, and catastrophic vehicular crashes as they commute home during times of peak physiological fatigue.
The economic toll is similarly staggering. Reduced productivity, absenteeism, presenteeism—where employees are physically at work but operating at a fraction of their cognitive capacity—and medical expenditures cost industrialized economies billions of dollars annually. Despite these high stakes, therapeutic interventions tailored specifically to early morning workers have remained virtually non-existent until now. Previously available wake-promoting agents, such as modafinil, were primarily studied and approved for overnight shift workers. Furthermore, these older medications often possess long half-lives that can inadvertently disrupt the sleep architecture when workers attempt to rest later in the day, creating a vicious cycle of chemical stimulation followed by chemically induced insomnia.
Evaluating Solriamfetol: A Novel Pharmacological Approach
Faced with a therapeutic vacuum, researchers at Mass General Brigham sought to determine whether solriamfetol could offer a safer, more effective alternative for early morning employees. Solriamfetol is a dual-acting dopamine and norepinephrine reuptake inhibitor that has already received regulatory approval from the U.S. Food and Drug Administration (FDA) to treat excessive daytime sleepiness in patients suffering from obstructive sleep apnea (OSA) and narcolepsy.
Because of its pharmacodynamic profile, investigators hypothesized that solriamfetol would provide sustained wakefulness throughout an eight-hour shift without exerting lingering stimulant effects that would sabotage the patient’s ability to sleep during their scheduled downtime. To test this hypothesis, the research team designed a rigorous, randomized, double-blind, placebo-controlled clinical trial.
The trial enrolled 78 participants, all of whom were confirmed early morning shift workers meeting stringent diagnostic criteria for shift work disorder. Over a four-week period, participants were randomly assigned to receive either daily doses of solriamfetol or an inactive placebo on their workdays. The trial utilized sophisticated evaluation metrics, including controlled laboratory assessments designed to measure the ability to maintain wakefulness in low-stimulation environments during hours corresponding to the participants’ typical shifts. Additionally, researchers tracked subjective reports from both the participants and their clinical evaluators regarding daily functioning, occupational performance, and overall quality of life.
Breakthrough Findings from the Clinical Trial
The results of the four-week trial offered definitive proof of solriamfetol’s efficacy. Participants who received the active drug demonstrated statistically significant and clinically meaningful improvements in alertness compared to those in the placebo group. During simulated work hours, the solriamfetol cohort was able to remain awake for substantially longer periods and exhibited marked reductions in subjective sleepiness.
Beyond objective laboratory metrics, the qualitative feedback gathered from participants and clinicians highlighted tangible improvements in everyday life. Workers reported an enhanced capacity to fulfill job responsibilities safely and efficiently, improved concentration during critical morning hours, and a better overall ability to manage daily domestic and professional tasks without experiencing debilitating exhaustion.
Dr. Charles A. Czeisler, senior physician and chief of the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine, as well as the senior author of the study, emphasized the profound significance of these outcomes. He noted that while modern society relies heavily on the labor of early morning workers—including nurses, manufacturing personnel, first responders, and sanitation workers—these individuals frequently bear a hidden biological cost. By demonstrating that a pharmacological intervention can safely sustain alertness across a full eight-hour shift, the research team has provided a viable clinical roadmap to mitigate these occupational hazards.
Similarly, Dr. Kirsi-Marja Zitting, an investigator in the same division and the first author of the study, underscored the physiological hurdles overcome by the trial participants. She pointed out that staying alert when the brain demands sleep requires overcoming immense biological resistance, and that providing these workers with targeted medical support validates an underserved patient population that has long been forced to quietly endure chronic fatigue.
Looking Ahead: Future Research and Regulatory Implications
While the findings from the Mass General Brigham trial represent a major milestone in sleep medicine, the authors and independent experts emphasize that this study is merely the foundational step in a broader scientific endeavor. The initial trial was constrained by a relatively modest sample size of 78 participants, lasted for a duration of four weeks, and focused exclusively on otherwise healthy adults who presented with shift work disorder.
Consequently, additional research is required to evaluate the long-term safety profile of solriamfetol when used continuously over extended periods. Questions regarding potential tolerance, cardiovascular impacts over years of use, and efficacy across more diverse demographic groups must be thoroughly explored through subsequent longitudinal studies.
Capitalizing on the momentum of this initial success, the research team has already initiated preparations for the next phase of investigation. Recruitment is currently underway for a follow-up clinical trial designed to examine the safety and efficacy of solriamfetol in overnight shift workers. Generating robust data across different categories of non-standard work schedules will be instrumental in supporting broader regulatory applications and potentially securing expanded clinical indications for treating shift work disorder comprehensively.
The study itself was a collaborative effort involving a multidisciplinary team of clinicians and researchers from Mass General Brigham. In addition to Dr. Zitting and Dr. Czeisler, the co-authors included Katherine R. Gilmore, Brandon J. Lockyer, Wei Wang, Nicolas C. Issa, Stuart F. Quan, Jonathan S. Williams, Jeanne F. Duffy, and Eileen B. Leary. Financial support for the research was provided through grants and resources from Jazz Pharmaceuticals, Axsome Therapeutics, and the Brigham and Women’s Hospital Center for Clinical Investigation, with the trial registered under the identifier NCT04788953.
Broader Societal and Policy Implications
As the global economy continues to demand round-the-clock operations, the health and safety of non-traditional shift workers can no longer be treated as a peripheral issue. The findings emerging from Mass General Brigham carry profound implications not only for clinical practice but also for corporate human resources policies, occupational health and safety regulations, and public infrastructure planning.
Employers who rely on early morning and overnight workforces may soon need to re-evaluate how they address worker fatigue. Historically, corporate strategies have focused on rudimentary measures such as scheduling adjustments, caffeine availability, and educational seminars on sleep hygiene. While these measures remain valuable, they often prove entirely inadequate against the powerful drive of circadian misalignment. The validation of pharmacological treatments like solriamfetol introduces a new paradigm in occupational medicine, where shift work disorder can be clinically diagnosed and medically managed in the same manner as other chronic medical conditions.
However, medical interventions should not be viewed as a silver bullet that excuses organizations from addressing the root systemic causes of worker exhaustion. Labor advocates and sleep specialists alike argue that pharmaceutical support must be paired with sensible scheduling practices. Whenever feasible, companies should implement forward-rotating shift schedules—moving from day to evening to night shifts, which aligns more naturally with the human body’s intrinsic tendency toward phase delay—limit consecutive early-morning shifts, and provide adequate rest intervals between work periods.
Furthermore, policymakers and regulatory bodies must take note of the intersection between sleep health and public safety. Commercial driving regulations, aviation safety rules, and medical residency hour caps have long recognized the dangers of acute sleep deprivation. Expanding medical awareness of shift work disorder among primary care physicians could lead to earlier diagnoses and interventions, preventing countless workplace accidents, reducing healthcare expenditures associated with chronic lifestyle diseases, and ultimately saving lives.
Conclusion
The groundbreaking clinical trial conducted by researchers at Mass General Brigham marks a critical turning point in the understanding and treatment of shift work disorder among the millions of individuals who power the early morning economy. By demonstrating that solriamfetol can safely and effectively enhance wakefulness, cognitive performance, and overall quality of life without severely disrupting subsequent rest, the study provides a much-needed medical tool to combat a pervasive occupational hazard.
As follow-up research gets underway to evaluate long-term outcomes and extend these findings to overnight workers, the medical community moves closer to a comprehensive framework for addressing circadian disruption. Ultimately, acknowledging the hidden biological costs borne by early morning workers and providing them with evidence-based therapeutic options is not merely a matter of pharmacological innovation—it is a fundamental necessity for protecting human health, preserving public safety, and fostering a more sustainable 24-hour society.
